Get the Stockscreener App
7.58
1.04%
-0.08
After Hours:
7.50
-0.08
-1.06%
Intensity Therapeutics Inc stock is traded at $7.58, with a volume of 30,544.
It is down -1.04% in the last 24 hours and down -17.32% over the past month.
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
See More
Previous Close:
$7.66
Open:
$7.5
24h Volume:
30,544
Relative Volume:
0.37
Market Cap:
$19.21M
Revenue:
-
Net Income/Loss:
$-11.74M
P/E Ratio:
-0.7171
EPS:
-10.5698
Net Cash Flow:
$-9.50M
1W Performance:
+29.79%
1M Performance:
-17.32%
6M Performance:
+10.25%
1Y Performance:
-87.04%
1-Day Range:
$7.50
$7.70
1-Week Range:
$5.76
$8.055
52-Week Range:
$4.6325
$62.49
Intensity Therapeutics Inc Stock (INTS) Company Profile
Name
Intensity Therapeutics Inc
Sector
Industry
Phone
203-221-7381
Address
1 ENTERPRISE DRIVE, SUITE 430, SHELTON
Compare INTS vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INTS
Intensity Therapeutics Inc
|
7.58 | 19.41M | 0 | -11.74M | -9.50M | -10.57 |
|
VRTX
Vertex Pharmaceuticals Inc
|
486.03 | 126.21B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
790.81 | 82.64B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
756.76 | 47.46B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.07 | 44.15B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
314.36 | 35.08B | 4.98B | 69.60M | 525.67M | 0.5198 |
Intensity Therapeutics Inc Stock (INTS) Latest News
Surprises Report: Whats next for Intensity Therapeutics Inc stock2025 Retail Activity & Free Community Consensus Stock Picks - baoquankhu1.vn
Buy Signal: Should I set a stop loss on Intensity Therapeutics IncJuly 2025 Earnings & Accurate Buy Signal Alerts - baoquankhu1.vn
Sentiment Watch: Can MAAS deliver alphaWeekly Risk Summary & Weekly High Potential Alerts - baoquankhu1.vn
Can Intensity Therapeutics Inc. stock beat market expectations this quarterWeekly Trade Analysis & Low Risk Investment Opportunities - mfd.ru
Is Intensity Therapeutics Inc.’s growth already priced inQuarterly Market Review & AI Enhanced Trading Signals - mfd.ru
Why did INTS stock plummet 25% today? - MSN
Why did INTS stock plummet 30% pre-market today? - MSN
CT biotech firm plans reverse stock split to regain Nasdaq compliance - Hartford Business Journal
What's going on with Intensity Therapeutics stock Friday? - MSN
Can Intensity Therapeutics Inc. disrupt its industryPortfolio Risk Report & Free Community Consensus Stock Picks - mfd.ru
Why Did INTS Stock Plummet 25% Today? - Stocktwits
Growth Review: Can Intensity Therapeutics Inc benefit from deglobalizationQuarterly Profit Review & Free Reliable Trade Execution Plans - baoquankhu1.vn
Intensity Therapeutics announces 1-for-25 reverse stock split By Investing.com - Investing.com Australia
Intensity Therapeutics Announces 1-for-25 Reverse Stock Split - TipRanks
Intensity Therapeutics (Nasdaq: INTS) Stock: Announces 1-for-25 Reverse Split to Meet Nasdaq Rule - CoinCentral
What's Going On With Intensity Therapeutics Stock Friday? - Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session - Benzinga
Intensity Therapeutics announces 1-for-25 reverse stock split - Investing.com
Intensity Therapeutics announces reverse stock split - marketscreener.com
Why Did INTS Stock Plummet 30% Pre-Market Today? - Menafn.com
Intensity Therapeutics Announces Reverse Stock Split - TradingView
Will Intensity Therapeutics Inc. stock gain from government policiesJuly 2025 Patterns & Low Risk High Win Rate Stock Picks - mfd.ru
All you need to know about Intensity Therapeutics Inc. (INTS) rating upgrade to buy - MSN
Weekly Earnings: Is SVRA a cyclical or defensive stockQuarterly Performance Summary & Technical Confirmation Alerts - baoquankhu1.vn
Intensity Therapeutics Gains AttentionStock Up 8% - Nasdaq
Risk Report: Is BRLSW affected by consumer sentimentWeekly Gains Summary & Verified Entry Point Detection - baoquankhu1.vn
Recap Report: Is Smithfield Foods Inc showing insider buyingGap Up & Reliable Volume Spike Alerts - baoquankhu1.vn
Why Is Retail Going Gaga Over INTS Stocks Today? - MSN
Volume Summary: Is Faraday Future Intelligent Electric Inc being accumulated by smart moneyLayoff News & Technical Buy Zone Confirmations - baoquankhu1.vn
Chart Watch: Is Intensity Therapeutics Inc stock a top performer YTD2025 Geopolitical Influence & Weekly High Return Stock Opportunities - baoquankhu1.vn
Stop Loss: Can Intensity Therapeutics Inc. ride the EV waveAnalyst Downgrade & Low Risk Investment Opportunities - baoquankhu1.vn
Should I hold or sell Intensity Therapeutics Inc. stock in 20252025 Short Interest & Stepwise Entry and Exit Trade Signals - bollywoodhelpline.com
Aug Mood: How do insiders feel about OptiNose Inc2025 Performance Recap & Low Drawdown Momentum Ideas - baoquankhu1.vn
Intensity therapeutics outlines 2026 priorities after clinical validation By Investing.com - Investing.com India
Layoff Watch: Is Intensity Therapeutics Inc stock a top pick in earnings season2025 Geopolitical Influence & High Conviction Trade Alerts - Bộ Nội Vụ
Intensity therapeutics outlines 2026 priorities after clinical validation - Investing.com
Intensity Therapeutics highlights 2025 milestones and outlines 2026 strategic priorities - marketscreener.com
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities - PR Newswire
Is Intensity Therapeutics Inc stock influenced by commodity pricesJuly 2025 Recap & Real-Time Volume Spike Alerts - baoquankhu1.vn
What insider trading reveals about Intensity Therapeutics Inc. stockEntry Point & Growth Oriented Trade Recommendations - Улправда
Why Intensity Therapeutics Inc. stock is rated strong buyLightweight Speed Options & trail grip notes for mixed terrain - Улправда
Can Intensity Therapeutics Inc. stock rebound after recent weaknessJuly 2025 Analyst Calls & Precise Entry and Exit Recommendations - Улправда
Can Intensity Therapeutics Inc. stock attract ESG capital inflowsShort Setup & Technical Pattern Alert System - Улправда
Why Intensity Therapeutics Inc. stock appeals to analysts2026 world cup usa national team group stage playmakers set piece tactics expert forecast analysis - Улправда
Intratumoral Cancer Therapies Market Expected to Gain Momentum Through 2034, According to DelveInsight - openPR.com
Intensity Therapeutics Inc Stock (INTS) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.90%
2.73%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):